Press release
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, California.\n\nPoster Presentation\n\nTitle: Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation\nPoster Number: P920\nSession: A76 Finger on the Pulse: Cardiopulmonary Dysfunction in Lung Disease\nDate: Sunday, May 18th\nTime: 11:30am – 1:15pm PDT\nLocation: Area G, Hall F (North Building, Exhibition Level), Moscone Center\n\nFollowing its presentation at the ATS 2025 International Conference, the poster will also be made available on the “Posters & Publications” section of the Gossamer Bio website at gossamerbio.com/science/posters-and-presentations/.\n\nGossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.\n\nAbout Gossamer Bio\n\nGossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250507040902/en/\n\nFor Investors and Media\nBryan Giraudo, Chief Operating Officer and Chief Financial Officer\nGossamer Bio Investor Relations\[email protected]\n\nSource: Gossamer Bio, Inc.","length":3891,"tagName":"div"}]